Cutaneous malignant melanoma is an aggressive form of skin cancer, characterized by strong chemoresistance and poor patient prognosis. The molecular mechanisms underlying its resistance to chemotherapy remain unclear but are speculated to involve the dysregulation of apoptotic pathways. In this study, we sought to determine whether PUMA (p53 upregulated modulator of apoptosis) contributes to human melanoma formation, tumor progression, and survival. We used tissue microarray and immunohistochemistry to examine PUMA expression in 107 primary melanomas, 51 metastatic melanomas, and 64 dysplastic nevi. Here we report that PUMA expression is significantly weaker in primary melanomas compared to dysplastic nevi (Po0.0001), and is further reduced in metastatic melanomas compared to primary tumors (P ¼ 0.001). We show that weak PUMA expression in melanoma correlates with poorer overall and diseasespecific 5-year survival (Po0.005 and Po0.001, respectively) of melanoma patients and that PUMA expression in tumor tissue is an independent predictor of both overall and disease-specific 5-year survival (P ¼ 0.05). Additionally, we show that exogenous PUMA expression in human melanoma cell lines (both wild type and mutant p53) results in significant apoptotic cell death. Our results suggest that PUMA expression may be an important prognostic marker for human melanoma and that adenoviral delivery of PUMA sensitizes melanoma cells to apoptosis.
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A major obstacle in treating metastatic melanoma is its stubborn resistance to conventional chemotherapies. Large randomized trials of anticancer drugs, including nitrosoureas, taxanes, vinca alkaloids, and platinum compounds, have failed to produce significant responses in melanoma tumors (Soengas and Lowe, 2003) . Even dacarbazine (DTIC), the only drug approved by the FDA specifically for metastatic melanoma, brings about complete response in only 5% of cases (Serrone et al., 2000) . The molecular basis for melanoma's drug resistance is poorly understood. Several mechanisms responsible for chemoresistance in other tumor types have been studied in melanoma, but do not appear to be major factors (reviewed by Grossman and Altieri, 2001 ). An alternative explanation for melanoma's drug resistance lies in the dysregulation of apoptosis. Most anticancer drugs exert their cytotoxic effects by inducing apoptosis (Fisher, 1994) ; therefore, treatment success depends upon functional cell death machinery. Defects in one or more components of the apoptotic pathway may result in resistance to drug-induced apoptosis.
Many molecular changes have the potential to cause apoptotic dysregulation, including activation of antiapoptotic factors, inactivation of proapoptotic effectors, and/or reinforcement of survival signals (Soengas and Lowe, 2003) . Overexpression of apoptosis inhibitors such as Survivin and FLIP (FLICE-inhibitory protein) has been reported in malignant melanoma (Irmler et al., 1997; Grossman et al., 1999) , whereas the apoptosis effector Apaf-1 has been found to be inactivated, presumably by methylation (Soengas et al., 2001) . Unlike many other human cancers, melanomas rarely harbor p53 mutations (Chin et al., 1998; Serrone and Hersey, 1999) . Therefore, other components of the p53 pathway, either upstream or downstream of p53, are likely defective in melanoma. One such candidate is the proapoptotic gene PUMA (p53 upregulated modulator of apoptosis).
PUMA is a BH3-only mitochondrial protein belonging to the Bcl-2 family of apoptotic regulators. PUMA was discovered in 2001 by two independent groups, each screening for p53-inducible target genes (Nakano and Vousden, 2001; Yu et al., 2001) . PUMA expression causes rapid p53-dependent apoptosis and growth inhibition (Yu et al., 2001) , induces cytochrome c release, and activates procaspases 3 and 9 (Nakano and Vousden, 2001) , suggesting a prominent role in the intrinsic apoptotic pathway.
We sought to determine whether PUMA has any relevance in the development and/or progression of malignant melanoma. We used tissue microarray and immunohistochemistry to determine levels of PUMA protein. Paraffin-embedded biopsies were obtained from the 1990-1998 archives of the Department of Pathology at Vancouver General Hospital. A total of 237 biopsies including 118 primary melanomas, 53 metastatic melanomas, and 66 dysplastic nevi were used for TMA construction. Due to loss of biopsy cores, 107 human primary melanomas, 51 metastatic melanomas, and 64 dysplastic nevi could be evaluated for PUMA staining. Clinicopathological data were available for melanoma cases.
PUMA staining was evaluated by two blinded independent observers (including one dermatopathologist) and a consensus score was reached for each biopsy core. Staining was mainly cytoplasmic; intensity was scored as weak
The staining pattern observed within individual biopsy cores was fairly homogenous; in 95% of nevi cores and 85% of tumor cores, all of the nevi/tumor cells exhibited uniform staining intensity. In the remaining 5% of nevi cores and 15% of tumor cores, where some degree of heterogeneity was observed, a staining score was assigned according to which intensity level was most prevalent throughout the core. Comparison of duplicate cores (from the same biopsy) revealed identical staining in 91% of nevi duplicates and 94% of tumor duplicates. In cases of inconsistent staining between duplicates, the core with the higher staining score was used for analyses. Differential staining of replicate cores likely reflects the heterogeneous and highly metastatic nature of malignant melanoma. As melanoma quickly progresses, associated changes in gene expression may occur nonuniformly throughout the tumor.
Although the level of PUMA varied in both nevi and melanoma tissues, PUMA expression was significantly weaker in primary melanoma than in dysplastic nevi (Po0.0001, w 2 test) ( Figure 1e ). PUMA expression was further reduced in metastatic melanomas, compared to primary tumors (P ¼ 0.001, Fisher's exact test). These results demonstrate for the first time that PUMA expression is lower in malignant melanoma compared to dysplastic nevi. This is significant because it identifies a possible point of dysfunction along the intrinsic cell death pathway that may contribute to malignant transformation.
To determine the implications of PUMA reduction in melanoma tissue, we examined the correlations between PUMA expression in tumors and clinicopathological parameters (Table 1) . Contingency table analyses revealed no associations between PUMA expression and gender, age, tumor thickness, ulceration, histological subtype, or anatomical site.
To examine the effect of PUMA expression on survival, Kaplan-Meier survival curves were plotted for patients whose primary tumors exhibited weak (1 þ ) PUMA staining versus those whose primary melanoma exhibited moderate or strong (2 þ , 3þ ) staining. PUMA expression in primary melanoma tissue correlated with both overall and disease-specific 5-year survival (P ¼ 0.01 and Po0.01, respectively, log-rank test) (Figure 2a) . The correlation is even more significant Figure 1 PUMA expression in human dysplastic nevi, primary melanoma, and metastatic melanoma tumor tissues. Paraffinembedded tissue blocks containing dysplastic nevi, primary melanoma, and metastatic melanoma biopsies were cored (0.6 mm diameter) in duplicate, transferred to a recipient block, sectioned (4 mm) with a microtome, and applied to adhesive-coated slides. Antigen retrieval was performed using 10 mM sodium citrate (pH 6.0). when primary and metastatic melanoma cases are combined for the analysis; both overall and diseasespecific 5-year survival rates are significantly worse for patients with weak (1 þ ) PUMA expression in tumor tissue compared to those with moderate or strong expression (2 þ , 3 þ ) (Po0.005 and Po0.001, respectively, log-rank test) (Figure 2b ). To determine whether PUMA expression could independently predict melanoma survival outcome, Cox multivariate regression analysis was employed to adjust for all clinicopathological factors (listed in Table 1 ). Multivariate analysis revealed that the overall 5-year mortality risk for melanoma patients with weak (1 þ ) PUMA expression was 2.33 times higher than for patients with moderate or strong (2 þ , 3þ ) PUMA expression (R 2 ¼ 2.33, P ¼ 0.05). In the case of disease-specific survival, the 5-year mortality risk was 2.89 times higher for patients with weak (1 þ ) PUMA expression over patients with moderate or strong (2 þ , 3 þ ) expression (R 2 ¼ 2.89, P ¼ 0.05). Our results clearly indicate that low PUMA expression in either primary or metastatic melanoma tissue is associated with poor prognosis, suggesting that PUMA reduction may serve as a molecular marker for aggressive disease.
PUMA is a potent proapoptotic effector that is rapidly induced in cells following DNA damage (Han et al., 2001) and is required for p53-induced apoptosis (Yu et al., 2003) . Induction of p53-mediated apoptosis is the principal mechanism by which most chemotherapeutic drugs kill tumor cells (Fisher, 1994) . Consequently, downregulation of PUMA may severely hamper a cell's ability to respond to chemotherapy. It has been shown that PUMA is necessary for the apoptosis induced by the DNA-damaging drug adriamycin in colorectal cancer cells (Yu et al., 2003) , and it is possible that other chemotherapeutic drugs also require PUMA. Reduced PUMA expression might explain why melanomas typically exhibit low apoptotic indices (Staunton and Gaffney, 1995; Glinsky et al., 1997) and highly chemoresistant phenotypes, despite their low (Chin et al., 1998; Serrone and Hersey, 1999) .
If low PUMA expression renders melanoma resistant to apoptosis, then exogenous expression of PUMA should reverse such resistance. To test this hypothesis, we infected four melanoma cell lines with an adenoviral construct bearing PUMAa cDNA (Figure 3) . We found that both wild-type p53 and mutant p53 melanoma cells underwent a significant degree of dose-dependent apoptosis following infection with ad-PUMA compared to infection with an ad-GFP control. This result suggests that adenoviral delivery of PUMA may be a valuable gene therapy tool for sensitizing melanoma tumors to apoptosis.
In our study, patients with weak PUMA expression had significantly poorer prognoses. As treatment histories were not available, it is not clear whether chemoresistance was responsible for these patients' deaths. However, the results of this study led us to speculate that reduced PUMA expression may contribute to chemoresistance and thus decreased survival in melanoma patients. Our recent work on melanoma cell lines, showing that PUMA-transfected cells undergo enhanced apoptosis following anticancer drug treatment compared to vector-transfected controls, further supports this idea (unpublished data).
Of course, it is unlikely that aberrant expression of a single gene leads to melanoma development and associated drug resistance. Dysregulation of several apoptotic regulators, in combination with PUMA loss, is probably responsible for melanoma chemoresistance. For example, the apoptotic inhibitors Mcl-1, Bcl-X L , XIAP, Livin, and Survivin are elevated in some melanoma cell lines, while proapoptotic Bax protein is abnormally low, compared to normal melanocytes (Bowen et al., 2003) . We propose a model in which PUMA downregulation in melanoma creates an apoptotic-resistant phenotype that responds poorly to chemotherapeutic drug treatment. Over the course of such treatment, cells exhibiting low PUMA expression enjoy a selective advantage, enabling them to survive and increase in proportion despite being subjected to proapoptotic stimuli. If treatment fails and metastasis occurs, the metastatic tissue is more likely to have reduced PUMA expression than was the primary tumor. This would explain our finding that PUMA reduction is more prevalent in metastatic than in primary melanoma tumors. Delivery of PUMA to melanoma tissue via adenoviral-based gene therapy may kill tumor cells and/or sensitize them to chemotherapy.
In conclusion, our study has demonstrated that PUMA expression is dramatically reduced in melanoma tumor tissue compared to dysplastic nevi, and is further reduced in metastatic melanomas compared to primary melanomas. We have shown a strong correlation between 5-year survival and PUMA expression in melanoma tissue, suggesting that reduced PUMA expression may serve as a molecular marker for aggressive disease. Finally, we have demonstrated that forced PUMA expression in melanoma cells causes significant apoptotic cell death. 
